IIQ
$46M—
Inoviq
Diagnostics · Oncology
Cancer diagnostics company developing EXO-NET exosome capture technology and SubB2M biomarker platform for early cancer detection.
No cash data on fileFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
—
Runway
—Market Cap
$46M
Burn Rate
—
Shares Outstanding
141M
Pipeline Assets
2
Latest Insight(1)
1 Apr 2026Insider TradeChange of Director's Interest Notice - Max Johnston
1 transaction·+$33k net buyJohnston: bought $33k
3M Price
IIQ.ASX$0.330-12.0% 3M
Low $0.320High $0.385
Pipeline Assets (2)
EXO-NETCancer diagnostics (multiple)
PreclinicalSubB2MCancer diagnostics
PreclinicalDiscovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
EXO-NET
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Transactions
6 transactionsLast 90dNet Buy
Buys6+6 vs prior
Sells0
Buy Value$122k
warning3 directors bought within 30 days (03-02 – 04-01) — $89k total
$33,0002026-04-01
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
4 competitor trialsPhase 2+ · Non-ASX
Cancer Diagnostics4 active trials
3 Ph2/31 Ph2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
1 paper
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Biochem Biophys Res Commun2026-04· SubB2M
Catalysts (3)
US CLIA laboratory partner announcement
UpcomingSpeculativearrow_upwardHigh30 Sept 2026
EXO-OC ovarian cancer test LDT readiness
UpcomingExpectedarrow_upwardHigh31 Dec 2026
SubB2M/neuCA15-3 breast cancer LDT launch
UpcomingExpectedarrow_upwardHigh31 Dec 2026
| Event | Type | Confidence | Impact | Date | Status |
|---|
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.
Announcements(5)
person
Insider Tradeauto_awesome
Change of Director's Interest Notice - Max Johnston1 Apr 2026
expand_more271KB
person
Insider Tradeauto_awesome
Change of Director's Interest Notice - Mary Harney29 Mar 2026
expand_more270KB
person
Insider Tradeauto_awesome
Change of Director's Interest Notice - Peter Gunzburg12 Mar 2026
expand_more296KB
person
Insider Tradeauto_awesome
Change of Director's Interest Notice - Peter Gunzburg2 Mar 2026
expand_more295KB
person
Insider Tradeauto_awesome
Change of Director's Interest Notice - Peter Gunzburg22 Feb 2026
expand_more295KB